Enhancing Cellular Uptake of Activable Cell-penetrating Peptide-doxorubicin Conjugate by Enzymatic Cleavage

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2012 May 24

PMID 22619516

Citations 44

Authors

Nian-Qiu Shi

Wei Gao

Bai Xiang

Xian-Rong Qi

Affiliations

Soon will be listed here.

Abstract

The use of activable cell-penetrating peptides (ACPPs) as molecular imaging probes is a promising new approach for the visualization of enzymes. The cell-penetrating function of a polycationic cell-penetrating peptide (CPP) is efficiently blocked by intramolecular electrostatic interactions with a polyanionic peptide. Proteolysis of a proteinase-sensitive substrate present between the CPP and polyanionic peptide affords dissociation of both domains and enables the activated CPP to enter cells. This ACPP strategy could also be used to modify antitumor agents for tumor-targeting therapy. Here, we aimed to develop a conjugate of ACPP with antitumor drug doxorubicin (DOX) sensitive to matrix metalloproteinase-2 and -9 (MMP-2/9) for tumor-targeting therapy purposes. The ACPP-DOX conjugate was successfully synthesized. Enzymatic cleavage of ACPP-DOX conjugate by matrix metalloproteinase (MMP)-2/9 indicated that the activation of ACPP-DOX occurred in an enzyme concentration-dependent manner. Flow cytometry and laser confocal microscope studies revealed that the cellular uptake of ACPP-DOX was enhanced after enzymatic-triggered activation and was higher in HT-1080 cells (overexpressed MMPs) than in MCF-7 cells (under-expressed MMPs). The antiproliferative assay showed that ACPP had little toxicity and that ACPP-DOX effectively inhibited HT-1080 cell proliferation. These experiments revealed that the ACPP-DOX conjugate could be triggered by MMP-2/9, which enabled the activated CPP-DOX to enter cells. ACPP-DOX conjugate may be a potential prodrug delivery system used to carry antitumor drugs for MMP-related tumor therapy.

Citing Articles

Applications of cell penetrating peptide-based drug delivery system in immunotherapy.

Du J, Zhang R, Jiang S, Xiao S, Liu Y, Niu Y Front Immunol. 2025; 16:1540192.

PMID: 39911386 PMC: 11794548. DOI: 10.3389/fimmu.2025.1540192.

Advancement and application of novel cell-penetrating peptide in cancer management.

Yadav S, Singh P 3 Biotech. 2023; 13(7):234.

PMID: 37323859 PMC: 10264343. DOI: 10.1007/s13205-023-03649-1.

In Silico Screening and Optimization of Cell-Penetrating Peptides Using Deep Learning Methods.

Park H, Park J, Kim M, Cho K, Shin J Biomolecules. 2023; 13(3).

PMID: 36979457 PMC: 10046020. DOI: 10.3390/biom13030522.

Fibronectin-targeting and metalloproteinase-activatable smart imaging probe for fluorescence imaging and image-guided surgery of breast cancer.

Cheng Z, Jin Y, Li J, Shi G, Yu L, Shao B J Nanobiotechnology. 2023; 21(1):112.

PMID: 36978072 PMC: 10053476. DOI: 10.1186/s12951-023-01868-5.

Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?.

Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M Acta Pharm Sin B. 2023; 13(2):498-516.

PMID: 36873165 PMC: 9978859. DOI: 10.1016/j.apsb.2022.07.020.

References

Das S, Banerji A, Frei E, Chatterjee A . Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008; 82(9-10):467-76. DOI: 10.1016/j.lfs.2007.12.013. View

Lewin M, Carlesso N, Tung C, Tang X, Cory D, Scadden D . Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000; 18(4):410-4. DOI: 10.1038/74464. View

Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann J, Mathieu D . Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs. 2001; 12(2):107-16. DOI: 10.1097/00001813-200102000-00003. View

Lindgren M, Rosenthal-Aizman K, Saar K, Eiriksdottir E, Jiang Y, Sassian M . Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol. 2005; 71(4):416-25. DOI: 10.1016/j.bcp.2005.10.048. View

Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M . Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release. 2006; 111(3):333-42. DOI: 10.1016/j.jconrel.2005.12.023. View

Olson E, Jiang T, Aguilera T, Nguyen Q, Ellies L, Scadeng M . Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A. 2010; 107(9):4311-6. PMC: 2840175. DOI: 10.1073/pnas.0910283107. View

Wender P, Mitchell D, Pattabiraman K, Pelkey E, Steinman L, Rothbard J . The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A. 2000; 97(24):13003-8. PMC: 27168. DOI: 10.1073/pnas.97.24.13003. View

Aroui S, Brahim S, Hamelin J, De Waard M, Breard J, Kenani A . Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Apoptosis. 2009; 14(11):1352-65. DOI: 10.1007/s10495-009-0397-8. View

Jiang T, Olson E, Nguyen Q, Roy M, Jennings P, Tsien R . Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004; 101(51):17867-72. PMC: 539314. DOI: 10.1073/pnas.0408191101. View

10.

Murphy G, Nagase H . Progress in matrix metalloproteinase research. Mol Aspects Med. 2008; 29(5):290-308. PMC: 2810947. DOI: 10.1016/j.mam.2008.05.002. View

11.

Bullok K, Dyszlewski M, Prior J, Pica C, Sharma V, Piwnica-Worms D . Characterization of novel histidine-tagged Tat-peptide complexes dual-labeled with (99m)Tc-tricarbonyl and fluorescein for scintigraphy and fluorescence microscopy. Bioconjug Chem. 2002; 13(6):1226-37. DOI: 10.1021/bc025573a. View

12.

Aroui S, Brahim S, De Waard M, Kenani A . Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Commun. 2009; 391(1):419-25. DOI: 10.1016/j.bbrc.2009.11.073. View

13.

Vives E, Schmidt J, Pelegrin A . Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta. 2008; 1786(2):126-38. DOI: 10.1016/j.bbcan.2008.03.001. View

14.

Wang P, Qi X . [The design and enzymatic hydrolysis of activatable cell-penetrating peptide]. Yao Xue Xue Bao. 2011; 45(8):1048-51. View

15.

Neumann U, Kubota H, Frei K, Ganu V, Leppert D . Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme. Anal Biochem. 2004; 328(2):166-73. DOI: 10.1016/j.ab.2003.12.035. View

16.

Ma D, Shi N, Qi X . Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells. Int J Pharm. 2011; 419(1-2):200-8. DOI: 10.1016/j.ijpharm.2011.08.001. View

17.

Albright C, Graciani N, Han W, Yue E, Stein R, Lai Z . Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Mol Cancer Ther. 2005; 4(5):751-60. DOI: 10.1158/1535-7163.MCT-05-0006. View

18.

Torchilin V, Levchenko T . TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci. 2003; 4(2):133-40. DOI: 10.2174/1389203033487298. View

19.

Nguyen Q, Olson E, Aguilera T, Jiang T, Scadeng M, Ellies L . Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A. 2010; 107(9):4317-22. PMC: 2840114. DOI: 10.1073/pnas.0910261107. View

20.

Santra S, Yang H, Stanley J, Holloway P, Moudgil B, Walter G . Rapid and effective labeling of brain tissue using TAT-conjugated CdS:Mn/ZnS quantum dots. Chem Commun (Camb). 2005; (25):3144-6. DOI: 10.1039/b503234b. View